Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02393716 · ClinicalTrials.gov registry record · NA
Endurant Evo US Clinical Trial
A NA study, sponsored by Medtronic Cardiovascular.
- Terminated
- Registry status
- NA
- Development phase
- 139
- Enrollment target
NCT02393716 is a NA study that was terminated before completion, run by Medtronic Cardiovascular. The registered enrollment target is 139 participants.
The verdict
NCT02393716, a NA study, was terminated before completion, sponsored by Medtronic Cardiovascular.
- TERMINATED
- Registry status
- NA
- Development phase
- 139 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that the Endurant Evo Abdominal Aortic Aneurysm (AAA) stent graft system is safe and effective for endovascular treatment of infrarenal abdominal aortic or aortoiliac aneurysms.
Interventions
- DEVICE Endurant Evo AAA Stent Graft System
- PROCEDURE Endovascular aneurysm repair (EVAR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2015-04 |
| Est. Completion | 2021-06-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02393716
The ClinicalTrials.gov registry entry for NCT02393716 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiovascular, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Endurant Evo AAA Stent Graft System is the first listed.
NCT02393716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02393716 about?
NCT02393716 is a clinical study titled "Endurant Evo US Clinical Trial". The purpose of this study is to demonstrate that the Endurant Evo Abdominal Aortic Aneurysm (AAA) stent graft system is safe and effective for endovascular treatment of infrarenal abdominal aortic or aortoiliac aneurysms.
What is the current status of trial NCT02393716?
This trial is currently terminated. It is a NA study. The enrollment target is 139 participants. The study started on 2015-04. Estimated completion is 2021-06-25.
What interventions are being tested in trial NCT02393716?
The interventions under investigation include: Endurant Evo AAA Stent Graft System (DEVICE), Endovascular aneurysm repair (EVAR) (PROCEDURE).
Who is sponsoring clinical trial NCT02393716?
This trial is sponsored by Medtronic Cardiovascular, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.